Table 2 BladMetrix sensitivity across tumor stages and grades
BlCa cases, discovery series (n = 26) | BlCa cases, hematuria series (n = 93) | |
|---|---|---|
Conclusive patients | 88.5% (23/26) | 95.7% (89/93) |
Stages | ||
Ta | 100% (11/11) | 85% (33/39) |
T1 | – | 97% (30/31) |
T2 | 100% (3/3) | 100% (9/9) |
T3 | 100% (4/4) | 100% (1/1) |
T4 | – | 100% (2/2) |
CIS | 80% (4/5) | 100% (7/7) |
Grade | ||
Low-grade | 100% (7/7) | 85% (23/27)* |
High-grade | 94% (15/16) | 95% (57/60)* |